Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia

Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous... Purpose This study evaluated pharmacokinetics (PK) and safety profiles of single agent arsenic trioxide (ATO, As O ) 2 3 administrated as continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Patients and methods Patients received 0.16 mg/kg ATO per day. ATO was given for 40 min infusion on the first day fol- lowed by 18–20 h daily at a very slow rate with infusion speed of 8 drips/min. During the first week, plasma samples were collected immediately before next administration on each day, and 0.5, 1, 2, 4, 8, 12 h after administration, at the end of III infusion (18 h) on day 7. Total arsenic was determined by ICPMS. Arsenic species, arsenious acid (As ) and its metabolites, V V monomethylarsonic acid (MMA ) and dimethylarsinic acid (DMA ), were quantified by UHPLC-ICPMS. Safety assessment and PK analysis was conducted. Results Hyperleukocytosis occurred in two patients and no severe toxicity was observed. Total arsenic gradually accumu- lated from 15.84 to 34.12 ng/mL during the first week of therapy. MMA /iAs increased and remained stable at value about V V III 0.6 after day 4, while DMA /MMA declined under 2 after day 4. Compared with 2 h infusion, clearance (CL) of As was http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Cancer Chemotherapy and Pharmacology Springer Journals

Clinical pharmacokinetics and safety profile of single agent arsenic trioxide by continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia

Loading next page...
 
/lp/springer_journal/clinical-pharmacokinetics-and-safety-profile-of-single-agent-arsenic-UCeSiVErFF
Publisher
Springer Journals
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Oncology; Pharmacology/Toxicology; Cancer Research
ISSN
0344-5704
eISSN
1432-0843
D.O.I.
10.1007/s00280-018-3606-8
Publisher site
See Article on Publisher Site

Abstract

Purpose This study evaluated pharmacokinetics (PK) and safety profiles of single agent arsenic trioxide (ATO, As O ) 2 3 administrated as continuous slow-rate infusion in patients with newly diagnosed acute promyelocytic leukemia. Patients and methods Patients received 0.16 mg/kg ATO per day. ATO was given for 40 min infusion on the first day fol- lowed by 18–20 h daily at a very slow rate with infusion speed of 8 drips/min. During the first week, plasma samples were collected immediately before next administration on each day, and 0.5, 1, 2, 4, 8, 12 h after administration, at the end of III infusion (18 h) on day 7. Total arsenic was determined by ICPMS. Arsenic species, arsenious acid (As ) and its metabolites, V V monomethylarsonic acid (MMA ) and dimethylarsinic acid (DMA ), were quantified by UHPLC-ICPMS. Safety assessment and PK analysis was conducted. Results Hyperleukocytosis occurred in two patients and no severe toxicity was observed. Total arsenic gradually accumu- lated from 15.84 to 34.12 ng/mL during the first week of therapy. MMA /iAs increased and remained stable at value about V V III 0.6 after day 4, while DMA /MMA declined under 2 after day 4. Compared with 2 h infusion, clearance (CL) of As was

Journal

Cancer Chemotherapy and PharmacologySpringer Journals

Published: May 29, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off